BCM
LNAI

BlueCrest Capital Management’s Lunai Bioworks LNAI Stock Holding History

BlueCrest Capital Management’s Portfolio LNAI Stock Details LNAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-233
Closed -$129K – 914
2019
Q1 		$129K Buy
+233
New +$136K 0.01% 1038

Other funds holding LNAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $535M AUM 19.4% 1-Year Est. Return

BlueCrest Capital Management's LNAI Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Lunai Bioworks (LNAI) in Q2 2019, closing a stake of 233 shares — an estimated $129K sold.

BlueCrest Capital Management first reported a position in LNAI in Q1 2019 and held it in 1 quarter. The position peaked at $129K in Q1 2019. 29 funds tracked by Wall St. Rank hold LNAI as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Lunai Bioworks position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 233 Lunai Bioworks shares in Q2 2019, an estimated $129K.
  • BlueCrest Capital Management first reported a position in Lunai Bioworks in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Lunai Bioworks position peaked at $129K in Q1 2019.
  • 29 funds tracked by Wall St. Rank held Lunai Bioworks as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.